{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003207","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.062730+00:00","generated_at":"2026-05-21T05:39:47.896180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform","bullets":["Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.","Cash balance of $3.2M at March 31, 2025; company pursuing near-term capital transactions to bolster liquidity.","Phase 2 gastric trial (NCT06251973) enrolling; new data shows agenT-797 activity in PD-1-resistant gastroesophageal cancers.","Complete remission in metastatic testicular cancer after single agenT-797 infusion without lymphodepletion or toxicity.","Selected for probable NIAID funding for GvHD program; strategic discussions underway across oncology and immunology."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003207","json":"https://secwatch.observer/filing/0001171843-25-003207.json","markdown":"https://secwatch.observer/filing/0001171843-25-003207.md","text":"https://secwatch.observer/filing/0001171843-25-003207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/0001171843-25-003207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325003207/f8k_051525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:39:47.896180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}